Jove
Visualize
Contact Us

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Long-term Outcomes Of Parp Inhibitors In Ovarian Cancer: Survival, Adverse Events, And Post-progression Insights.
  1. Home
  3. Long-term Outcomes Of Parp Inhibitors In Ovarian Cancer: Survival, Adverse Events, And Post-progression Insights.

Related Experiment Video

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K

Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights.

V Tuninetti1, J A Marín-Jiménez2, G Valabrega1

  • 1Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy.

ESMO Open
|November 14, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Poly-ADP-ribose polymerase inhibitors (PARPis) offer survival benefits in BRCA-mutated ovarian cancer (OC). However, concerns exist regarding overall survival and risks like myelodysplastic syndrome/acute myeloid leukemia in other OC types.

Keywords:
PARP inhibitorsmyelodysplastic syndromeovarian canceroverall survivalpost-progressiontoxicity

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.9K

Related Experiment Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.9K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Poly-ADP-ribose polymerase inhibitors (PARPis) have transformed ovarian cancer (OC) treatment, particularly for BRCA-mutated (BRCAmut) and homologous recombination deficiency (HRD)-positive cases.
  • Long-term data support PARPi maintenance therapy post-first-line chemotherapy.
  • Recent findings raise concerns about overall survival (OS) in non-BRCAmut OC, increased myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) incidence, and outcomes after subsequent platinum chemotherapy.

Purpose of the Study:

  • To discuss long-term follow-up results from phase III trials in pretreated OC patients.
  • To summarize new evidence on MDS/AML risk and post-progression efficacy after PARPi.
  • To emphasize the need for long-term follow-up and real-world data to guide PARPi discontinuation strategies.

Main Methods:

  • Review of long-term follow-up data from phase III trials in pretreated ovarian cancer patients.
  • Analysis of newly available evidence on myelodysplastic syndrome/acute myeloid leukemia incidence.
  • Examination of post-progression efficacy results following PARPi treatment.

Main Results:

  • Long-term analyses support PARPi maintenance in BRCAmut/HRD-positive OC.
  • Concerns identified regarding detrimental OS in non-BRCAmut OC.
  • Increased incidence of MDS/AML and unfavorable outcomes with subsequent platinum chemotherapy noted.

Conclusions:

  • The FDA withdrew PARPi indications for pretreated OC based on long-term follow-up data.
  • Defining optimal PARPi discontinuation timing requires further investigation using long-term and real-world data.
  • Biomarkers are crucial for identifying patients who benefit from long-term PARPi maintenance versus those with early resistance.